A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC) Meeting Abstract

  

Authors:	Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; Steinbrecher, J. E.; Danila, D. C.; Curley, T.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Scher, H. I.
Abstract Title:	A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
Meeting Title:	48th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	30
Issue:	15 Suppl.
Meeting Dates:	2012 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2012-05-20
Language:	English
ACCESSION:	WOS:000318009802763
PROVIDER:	wos
DOI:	10.1200/jco.2012.30.15_suppl.TPS4697
Notes:	Meeting Abstract: TPS4697 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/152163